WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV)
21 December 2021
| Guideline

Overview
This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. This document includes guidance on an important additional option for cervical screening, the use of mRNA (messenger RNA) HPV testing. This gives countries additional options when considering which type of HPV nucleic acid amplification tests (NAAT) to use in their screening programs.
WHO Team
Global HIV, Hepatitis and STIs Programmes (HHS),
Guidelines Review Committee,
Sexual and Reproductive Health and Research (SRH)
Editors
World Health Organization
Number of pages
63
Reference numbers
ISBN: 978 92 4 0040434